Td Asset Management Inc Bei Gene, Ltd. Transaction History

Td Asset Management Inc

  • $107 Billion
  • Q3 2024

A detailed history of Td Asset Management Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Td Asset Management Inc holds 125,412 shares of BGNE stock, worth $23.9 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
125,412
Previous 114,378 9.65%
Holding current value
$23.9 Million
Previous $16.3 Million 72.55%
% of portfolio
0.03%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024
BUY
$143.93 - $224.51 $1.59 Million - $2.48 Million
11,034 Added 9.65%
125,412 $28.2 Million
Q2 2024

Aug 02, 2024
BUY
$129.52 - $174.32 $207,102 - $278,737
1,599 Added 1.42%
114,378 $16.3 Million
Q1 2024

May 08, 2024
BUY
$141.8 - $181.47 $1.58 Million - $2.02 Million
11,116 Added 10.93%
112,779 $17.6 Million
Q4 2023

Feb 12, 2024
BUY
$158.67 - $201.58 $223,248 - $283,623
1,407 Added 1.4%
101,663 $18.3 Million
Q3 2023

Oct 27, 2023
BUY
$179.87 - $225.13 $8.64 Million - $10.8 Million
48,018 Added 91.92%
100,256 $18 Million
Q2 2023

Aug 09, 2023
BUY
$178.3 - $266.78 $3.13 Million - $4.68 Million
17,555 Added 50.62%
52,238 $9.31 Million
Q1 2023

May 10, 2023
BUY
$215.53 - $274.5 $3.61 Million - $4.6 Million
16,748 Added 93.38%
34,683 $7.48 Million
Q4 2022

Feb 06, 2023
BUY
$125.51 - $229.3 $119,736 - $218,752
954 Added 5.62%
17,935 $3.94 Million
Q3 2022

Nov 07, 2022
SELL
$131.8 - $202.24 $176,480 - $270,799
-1,339 Reduced 7.31%
16,981 $2.31 Million
Q2 2022

Aug 04, 2022
SELL
$121.11 - $216.05 $683,665 - $1.22 Million
-5,645 Reduced 23.56%
18,320 $2.97 Million
Q1 2022

May 10, 2022
SELL
$146.52 - $269.56 $82,197 - $151,223
-561 Reduced 2.29%
23,965 $4.52 Million
Q4 2021

Feb 10, 2022
BUY
$248.56 - $389.34 $23,116 - $36,208
93 Added 0.38%
24,526 $6.65 Million
Q3 2021

Nov 09, 2021
BUY
$249.6 - $403.14 $24,211 - $39,104
97 Added 0.4%
24,433 $8.87 Million
Q2 2021

Aug 11, 2021
SELL
$292.75 - $367.01 $1.47 Million - $1.84 Million
-5,017 Reduced 17.09%
24,336 $7.7 Million
Q1 2021

May 14, 2021
BUY
$260.64 - $382.12 $276,539 - $405,429
1,061 Added 3.75%
29,353 $10.2 Million
Q4 2020

Feb 16, 2021
SELL
$221.31 - $316.61 $1.53 Million - $2.18 Million
-6,893 Reduced 19.59%
28,292 $7.31 Million
Q3 2020

Nov 10, 2020
BUY
$189.18 - $286.44 $1.61 Million - $2.44 Million
8,534 Added 32.02%
35,185 $10.1 Million
Q2 2020

Aug 13, 2020
BUY
$123.9 - $195.41 $322,140 - $508,066
2,600 Added 10.81%
26,651 $5.02 Million
Q1 2020

May 15, 2020
SELL
$121.84 - $173.19 $134,024 - $190,509
-1,100 Reduced 4.37%
24,051 $2.96 Million
Q4 2019

Feb 11, 2020
SELL
$115.78 - $208.34 $415,071 - $746,898
-3,585 Reduced 12.48%
25,151 $4.17 Million
Q3 2019

Nov 07, 2019
SELL
$120.61 - $148.29 $289,464 - $355,896
-2,400 Reduced 7.71%
28,736 $3.52 Million
Q2 2019

Aug 01, 2019
BUY
$113.99 - $146.86 $101,223 - $130,411
888 Added 2.94%
31,136 $3.86 Million
Q1 2019

May 08, 2019
BUY
$122.82 - $151.83 $49,128 - $60,732
400 Added 1.34%
30,248 $3.99 Million
Q4 2018

Feb 01, 2019
BUY
$107.01 - $175.15 $342,432 - $560,480
3,200 Added 12.01%
29,848 $4.19 Million
Q3 2018

Nov 01, 2018
SELL
$152.62 - $189.66 $259,454 - $322,422
-1,700 Reduced 6.0%
26,648 $4.59 Million
Q2 2018

Jul 31, 2018
BUY
$152.5 - $216.77 $122,000 - $173,416
800 Added 2.9%
28,348 $4.36 Million
Q1 2018

May 11, 2018
BUY
$97.41 - $177.22 $563,029 - $1.02 Million
5,780 Added 26.55%
27,548 $4.63 Million
Q4 2017

Feb 02, 2018
SELL
$79.6 - $114.73 $143,280 - $206,514
-1,800 Reduced 7.64%
21,768 $2.13 Million
Q3 2017

Nov 09, 2017
BUY
$66.19 - $103.46 $1.56 Million - $2.44 Million
23,568
23,568 $2.44 Million

Others Institutions Holding BGNE

# of Institutions
250
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email